Cell and gene based methods to improve cardiac function

Patent metadata

Field	Value
Publication number	US-9868937-B2
Application number	US-201214122226-A
Country	US
Kind code	B2
Filing date	May 29, 2012
Priority date	May 26, 2011
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.

First claim

What is claimed is:

1. A pharmaceutical composition comprising a first viral vector comprising a first nucleic acid sequence encoding ribonucleotide reductase subunit R1 and a second viral vector comprising a second nucleic acid sequence encoding ribonucleotide reductase subunit R2, said first nucleic acid sequence and second nucleic acid sequence being operably linked to a cardiac-specific promoter, wherein said cardiac-specific promoter comprises the nucleic acid sequence SEQ ID NO: 1.

2. A pharmaceutical composition comprising cardiomyocytes containing a first expression vector comprising a first nucleic acid sequence encoding ribonucleotide reductase subunit R1 and a second expression vector comprising a second nucleic acid sequence encoding ribonucleotide reductase subunit R2, said first nucleic acid sequence and second nucleic acid sequence being operably linked to a promoter that induces overexpression of R1 and R2, wherein said promoter that induces overexpression of R1 and R2 comprises the nucleic acid sequence SEQ ID NO: 1.

3. The pharmaceutical composition of claim 1 , wherein said first and second viral vectors are a single viral vector comprising the first nucleic acid sequence, the second nucleic acid sequence, and the cardiac-specific promoter.

4. The pharmaceutical composition of claim 1 , wherein said first and second viral vectors are adeno-associated viral vectors.

5. The pharmaceutical composition of claim 1 , wherein at least one of said first and second viral vectors is an adeno-associated virus type 6 (AAV6) vector.

6. The pharmaceutical composition of claim 1 , further comprising:
a nucleic acid sequence encoding a cTnC variant having a L48Q amino acid substitution, wherein said cTnC variant has an increased binding affinity for Ca 2+ .

7. The pharmaceutical composition of claim 6 , further comprising:
a CMV promoter operably linked to the nucleic acid sequence encoding the cTnC variant.

8. The pharmaceutical composition of claim 1 , further comprising:
a nucleic acid sequence encoding a cTnC variant having an amino acid substitution selected from I61Q and L57Q, wherein said cTnC variant has a decreased binding affinity for Ca 2+ .

9. The pharmaceutical composition of claim 8 , further comprising:
a CMV promoter operably linked to the nucleic acid sequence encoding the cTnC variant.

10. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is an injectable to be administered to a subject by at least one of systemic administration, intravenous administration, and intramyocardial injection.

11. The pharmaceutical composition of claim 1 , wherein at least one of said first and second viral vectors further comprises a transduction reporter.

12. The pharmaceutical composition of claim 2 , wherein said first and second expression vectors are part of a single vector comprising the first nucleic acid sequence encoding R1 and the second nucleic acid sequence encoding R2.

13. The pharmaceutical composition of claim 2 , wherein said first and second expression vectors are adeno-associated viral vectors.

14. The pharmaceutical composition of claim 2 , wherein at least one of said first and second expression vectors is an adeno-associated virus type 6 (AAV6) vector.

15. The pharmaceutical composition of claim 2 , wherein at least one of said first and second expression vectors further comprises a transduction reporter.

16. The pharmaceutical composition of claim 2 , wherein said cardiomyocytes are derived from at least one of embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells.

17. The pharmaceutical composition of claim 16 , wherein said cardiomyocytes are of mammalian origin.

18. The pharmaceutical composition of claim 2 , wherein said cardiomyocytes are grafted to the myocardium of a subject.

Assignees

• Regnier Michael
• Laflamme Michael
• Murry Charles
• Korte F Steven
• Lundy Scott
• Hauschka Stephen Denison
• Chamberlain Jeffrey S
• Odom Guy
• Univ Washington

Inventors

• Regnier Michael
• Laflamme Michael
• Murry Charles
• Korte F Steven
• Lundy Scott
• Hauschka Stephen Denison
• Chamberlain Jeffrey S
• Odom Guy

Classifications

• C12N15/86

  Viral vectors · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• C12N2750/14132

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N15/8509

  for producing genetically modified animals, e.g. transgenic · CPC title

• C12Y117/04001 Primary

  Ribonucleoside-diphosphate reductase (1.17.4.1) · CPC title